Advancements in Urine-Based Testing and Treatments Show Promise for Bladder Cancer Survival
A study published in BMC Women's Health utilized urine metabolomics to assess the efficacy of fertility-sparing treatment in endometrial cancer (EC) patients. The researchers analyzed urine samples using ultra-performance liquid chromatography mass spectrometry (UPLC-MS) and identified distinct metabolites and altered metabolic pathways. They developed a panel of biomarkers that demonstrated high predictive ability in identifying patients with complete remission (CR). The panel consisted of Baicalin, 5beta-1,3,7 (11)-Eudesmatrien-8-one, Indolylacryloylglycine, Edulitine, and Physapubenolide. This non-invasive approach offers a less invasive means of monitoring treatment efficacy and may aid in evaluating fertility-sparing treatments for EC patients. Further research is needed to validate the biomarker panel in larger populations.